Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > expiration of options

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Jun 21, 2024 12:09pm

59 Views

Post# 36100135

RE:RE:RE:RE:RE:RE:RE:expiration of options

There is only about 10 people that post on here. There are sites where there are thousands posting. U pumpers need to grow up. The site soes not revolve around ur narrative. They would chew you up and spit u out on the other sites.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments